EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma

[1]  J. Bai,et al.  Role of EZH2 in oral squamous cell carcinoma carcinogenesis. , 2014, Gene.

[2]  Wang Kai,et al.  MicroRNA‐106b regulates the tumor suppressor RUNX3 in laryngeal carcinoma cells , 2013 .

[3]  R. Mehra,et al.  Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. , 2012, Cancer research.

[4]  Peng Zhang,et al.  RUNX3 Mediates Suppression of Tumor Growth and Metastasis of Human CCRCC by Regulating Cyclin Related Proteins and TIMP-1 , 2012, PloS one.

[5]  Gaoxi Xiao,et al.  RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor α , 2012, Oncogene.

[6]  M. Hung,et al.  The role of EZH2 in tumour progression , 2011, British Journal of Cancer.

[7]  Yaxin Han,et al.  The role of the tumor suppressor RUNX3 in giant cell tumor of the bone. , 2011, International journal of oncology.

[8]  Colin Logie,et al.  The human histone H3 complement anno 2011. , 2011, Biochimica et biophysica acta.

[9]  Amy Y. Chen,et al.  Temporal trends in the treatment of early- and advanced-stage laryngeal cancer in the United States, 1985-2007. , 2011, Archives of otolaryngology--head & neck surgery.

[10]  M. Fälth,et al.  EZH2 Depletion Blocks the Proliferation of Colon Cancer Cells , 2011, PloS one.

[11]  Jun Yu,et al.  EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. , 2011, Cancer research.

[12]  A. Chase,et al.  Aberrations of EZH2 in Cancer , 2011, Clinical Cancer Research.

[13]  H. Becher,et al.  Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis , 2011, European Archives of Oto-Rhino-Laryngology.

[14]  Guy Sauvageau,et al.  Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. , 2010, Cell stem cell.

[15]  C. Allis,et al.  Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers , 2010, Nature Reviews Cancer.

[16]  Manuel Salto-Tellez,et al.  Molecular pathology of RUNX3 in human carcinogenesis. , 2009, Biochimica et biophysica acta.

[17]  L. Miller,et al.  CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells , 2009, PloS one.

[18]  S. Dhanasekaran,et al.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer , 2008, Oncogene.

[19]  A. Ventura,et al.  Down-regulation of Enhancer of Zeste-2 decreases growth of estrogen receptor negative invasive breast carcinoma and requires BRCA1 , 2008, Oncogene.

[20]  V. Bilim,et al.  Regulation of Pancreatic Tumor Cell Proliferation and Chemoresistance by the Histone Methyltransferase Enhancer of Zeste Homologue 2 , 2008, Clinical Cancer Research.

[21]  A. Ochiai,et al.  Enhancer of Zeste Homologue 2 (EZH2) Down-regulates RUNX3 by Increasing Histone H3 Methylation*S⃞ , 2008, Journal of Biological Chemistry.

[22]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[23]  M. Bollen,et al.  The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2 , 2007, Oncogene.

[24]  S. Berger.  The complex language of chromatin regulation during transcription , 2007, Nature.

[25]  F. Hamdy,et al.  EZH2 promotes proliferation and invasiveness of prostate cancer cells , 2007, The Prostate.

[26]  S. Hirohashi,et al.  Genome‐wide array‐based comparative genomic hybridization analysis of pancreatic adenocarcinoma: Identification of genetic indicators that predict patient outcome , 2007, Cancer science.

[27]  Hans Clevers,et al.  Mining the Wnt pathway for cancer therapeutics , 2006, Nature Reviews Drug Discovery.

[28]  Tapio Visakorpi,et al.  The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancer , 2006, Genes, chromosomes & cancer.

[29]  Johan Eide,et al.  Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  M. von Knebel Doeberitz,et al.  Wnt/β‐catenin‐pathway as a molecular target for future anti‐cancer therapeutics , 2005 .

[31]  Ajamete Kaykas,et al.  WNT and β-catenin signalling: diseases and therapies , 2004, Nature Reviews Genetics.

[32]  D. Levanon,et al.  Structure and regulated expression of mammalian RUNX genes , 2004, Oncogene.

[33]  Hyeon Joo Lee,et al.  Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma , 2004, Laboratory Investigation.

[34]  Kazuhiro Yoshida,et al.  Frequent Loss of RUNX3 Expression by Promoter Hypermethylation in Gastric Carcinoma , 2004, Pathobiology.

[35]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[37]  S. Nomoto,et al.  Frequent allelic imbalance suggests involvement of a tumor suppressor gene at 1p36 in the pathogenesis of human lung cancers , 2000, Genes, chromosomes & cancer.

[38]  He Wang,et al.  [Expressions of EZH2 and RUNX3 in renal cell carcinoma and their clinical significance]. , 2013, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology.

[39]  R. Mehra,et al.  1 Polycomb protein EZH 2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer , 2012 .

[40]  J. Khan,et al.  EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. , 2012, Cancer research.

[41]  Vincenzo Pirrotta,et al.  Polycomb silencing mechanisms and the management of genomic programmes , 2007, Nature Reviews Genetics.

[42]  Randall T Moon,et al.  WNT and beta-catenin signalling: diseases and therapies. , 2004, Nature reviews. Genetics.